View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Credit Morning 02/11/2026

Imerys: French State is investing in the Emili Lithium Project|Downgrade from BB-/negative CW to B/negative outlook by Fitch|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 11/02/2026

Imerys : l’Etat entre au capital du projet EMILI (lithium)|Downgrade de la note de 'BB-' CW négatif à B/outlook négatif par Fitch|

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Andreas Riemann
  • Andreas Riemann
Carole Braudeau
  • Carole Braudeau

Credit Morning 02/10/2026

NIH: SNCF ordered to pay € 270m in compensation in the Gare du Nord case|Clarifications from Eramet on the temporary exemption of duty of its CFO|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 10/02/2026

NIH : la SNCF condamnée à verser une indemnité de 270 m EUR dans le dossier de la Gare du Nord|Clarifications d’Eramet sur la dispense d’activité temporaire de son CFO|

Arancha Pineiro
  • Arancha Pineiro

KERING: RDOS. 2025 (ANÁLISIS BANCO SABADELL)

Rdos. 4T'25 vs 4T'24: Ventas: 3.673 M euros (-16,3% vs -14,4% BS(e) y -14,1% consenso). Rdos. 2025 vs 2024: Ventas: 14.675 M euros (-14,7% vs -14,1% BS(e) y -14,1% consenso); EBIT: 1.631 M euros (-36,1% vs -33,0% BS(e) y -35,9% consenso); BDI recurrente: 532,0 M euros (-53,0% vs -39,6% BS(e) y -38,0% consenso).

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch